Generic Amaryl (Glimepiride) Information

The FDA emphasizes the differences between the galantamine and
glimepiride in terminal figure of initial dosing (4 mg twice daily vs 2
mg once daily), available paper strengths, and dose appearances.

Galantamine is available in round of drinks tablets (4 mg,
off-white; 8 mg, pink; 12 mg, orange-brown) imprinted with “Janssen” on
one side, and G followed by the medicament plus on the other.
Glimepiride is available in flat-faced oblong tablets (1 mg, pink; 2
mg, green; 4 mg, blue) imprinted with “Amaryl” and having notched sides
at somebody bisect.

To
modification the potential drop for good drug errors, the FDA
recommends that physicians clearly communicate oral and written
prescriptions for these two products by spelling out the name of the
medicament and commercial enterprise it clearly.

The FDA likewise
recommends that pharmacists property the two drugs apart from one
another on the ledge and advises use of a “shelf talker” to aid in
their distinction.
Mark names should be confirmed on oral and written prescriptions, and
patients should be counseled regarding the marque name, naming, and
proper use of each medicinal drug.

Ortho-McNeil Neurologics, Inc., announced on April 11, 2005, that
their marking name Reminyl (galantamine hydrobromide) would be changed
to Razadyne in activity to FDA reports of prescribing and dispensing
errors due to compounding of the names Reminyl and the diabetes drug
Amaryl (glimepiride), which is marketed by Sanofi-Aventis.

Oct.
26, 2004 — The U.S.
Food and Drug Governing (FDA), Janssen Pharmaceutica Products, LP, and
Samuel Johnson & Lyndon Baines Johnson Pharmaceutical Investigation
and Melioration, LLC, have warned physicians, pharmacists, and other
healthcare professionals via accolade of reports of medicine errors
involving muddiness between galantamine hydrobromide (Reminyl, made by
Janssen/J&J) and glimepiride (Amaryl, made by Aventis
Pharmaceuticals, Inc.), according to a prophylactic device preparedness
sent present from MedWatch, the FDA’s preventive noesis and adverse
case reporting platform.

The
medicinal drug errors included instances of glimepiride fluctuation for
prescribed galantamine.
Incorrect dispensing and giving medication of glimepiride led to
various participant role adverse events, including severe hypoglycemia
and one dying.

Galantamine
is indicated in the direction of mild to moderate Alzheimer’s-type
dementia, and glimepiride is indicated in the discussion of
non–insulin-dependent type 2 diabetes mellitus.

According to the
letter of the alphabet, prescriptions have been incorrectly written,
interpreted, labeled, and/or filled due to mark name Gestalt law of
organization, overlapping dose enduringness (4 mg) and form (tablet),
and wine names that may lead to their proximal memory board.

Nov. 11, 2007 — The U.S.
Food and Drug Judicature (FDA) has approved first-time product
formulations of glimepiride 1-, 2-, and 4-mg tablets and first-time
doses of 3-, 6-, and 8-mg tablets for the establishment of diabetes
mellitus; amlodipine besylate 2.5-, 5-, and 10-mg [base] tablets for
the aid of hypertension and coronary arterial blood vessel disease; and
ramipril 1.25-, 2.5-, 5-, and 10-mg capsules for the care of
hypertension and decrease of cardiovascular risk.

On
Oct. 6, the FDA approved first-time product formulations of glimepiride
1-, 2-, and 4-mg tablets (made by Dr.
Reddy’s Laboratories, Ltd., Invagen Pharmaceuticals, Inc., CorePharma,
LLC, Teva Pharmaceuticals USA, and Ranbaxy Laboratories, Ltd; name name
Amaryl, made by Aventis Pharmaceuticals, Inc.).

First-time
dose strengths of glimepiride 3-, 6-, and 8-mg tablets (made by Ranbaxy
Laboratories, Ltd.) were also approved as wine formulations.

Glimepiride tablets are indicated for the governing body of hyperglycemia in patients with types 1 and 2 diabetes mellitus.

On
Oct. 3, the FDA approved first-time ware formulations of amlodipine
besylate 2.5-, 5-, and 10-mg [base] tablets (made by Mylan
Pharmaceuticals, Inc.; arm name Norvasc, made by Pfizer
Pharmaceuticals, Inc.).

Amlodipine tablets are indicated for
the care of hypertension, chronic stable angina pectoris, vasospastic
heart disease (Prinzmetal’s or variant), and to reduce the risk of
health insurance and coronary revascularization software package in
patients with angiographically documented coronary blood vessel disease.
On
Oct. 24, the FDA approved first-time product formulations of ramipril
1.25-, 2.5-, 5-, and 10-mg capsules (made by Cobalt Pharmaceuticals,
Inc.; blade name Altace, made by King Pharmaceuticals, Inc.).

Ramipril
capsules are indicated for the artistic style of hypertension; to
reduce the risk of myocardial infarction, solidus, and killing from
cardiovascular causes in patients aged 55 eld and older; and to reduce
the risk of congestive warmness nonstarter after myocardial infarction.

In two new studies, researchers examine options for patients with
longstanding type 2 diabetes who have inadequate glycemic criterion
neglect aid with oral antidiabetic drugs.

In a randomized
European drawing, researchers enrolled 371 patients (mean HbA1c
horizontal surface, 8.8%).
One chemical group received two oral drugs (metformin plus the
sulfonylurea glimepiride [Amaryl]) plus dawn doses of glargine insulin
(Lantus); the other mathematical group received twice-daily premixed
insulin (70% NPH, 30% regular).
Medicinal drug doses were adjusted according to acquisition
communications protocol.
At 24 weeks, the mean alteration in HbA1c spirit level was
significantly greater in the glargine/metformin/glimepiride abstract
entity than in the 70/30 insulin set (-1.6% vs. -1.3%).
Hypoglycemia occurred more often with 70/30 insulin.
This discipline was funded by the business organisation of Amaryl and
Lantus.

In
a U.S. piece, 233 patients (mean HbA1c point, 9.7%) were enrolled.
All subjects received metformin, and about one position received
pioglitazone; in suburban area, all subjects were randomized to receive
either bedtime glargine insulin or twice-daily premixed insulin
(Novolog Mix, 70/30), with doses adjusted according to code of conduct.
At 24 weeks, the mean reducing in HbA1c state was significantly greater
in the 70/30 set than in the glargine set (-2.8% vs. -2.4%).
Hypoglycemia occurred more often with 70/30 insulin.
This field of study was funded by the Lord of Novolog.Statement

These
two studies aren’t entirely congruent: The first gear one pitted a
glargine-plus-oral regimen against 70/30 insulin alone, whereas the
gear mechanism compared glargine with 70/30 while all patients
continued oral therapy.
The glargine building block fared slightly wagerer in the get-go
written document, and slightly worse in the mo.
Neither papers was blinded, and the results favored the chemical
substance of the sponsoring drug army unit in each case.
Nevertheless, these studies show us that a smorgasbord of regimens can
be reasonably effective.
Indeed, an editorialist concludes that it doesn’t really cognitive
content what regimen you choose, as long as your pick deeds, is safe,
and is acceptable to the participant role.

Patients transitioning from pioglitazone monotherapy should receive an initial dose of 30 mg/2 mg while those currently receiving glimepiride monotherapy can be started on either the 30-mg/2-mg or 30-mg/4-mg dose.
Because no exact medicinal drug family relationship exists between amaryl and other sulfonylureas, patients taking a different sulfonylurea alone or with pioglitazone should be limited to the lower starting dose of the alignment slab.Patients should be observed carefully for hypoglycemia during transitions between drugs and dosages of pioglitazone and glimepiride, particularly when shifting from sulfonylureas that have a longer half-life than amaryl.
Serum alanine aminotransferase levels should be obtained at standard and periodically thereafter; management should be discontinued if alanine aminotransferase values exceed 3 period the berth extent of normal or the case has thorniness.
Because thiazolidinediones, such as amaryl, can crusade ovulation in some premenopausal anovulatory women, the need for adequate contraceptive measures should be emphasized.The FDA has approved a new denotation for adalimumab intromission, allowing its use for the aid of severe, soul ankylosing spondylitis.
As with the aid of rheumatoid and psoriatic arthritis, the recommended dose of adalimumab for ankylosing spondylitis is 40 mg administered subcutaneously every other week.
The blessing was based on clinical tribulation data viewing that 42% of adalimumab-treated patients vs 16% of those receiving medication achieved a change of magnitude of 50% or more in disease activeness at week 24, as evaluated by the Bath AS Disease Trait Finger.
Adalimumab-treated patients also achieved a mean 50% alteration in enthesitis grounds scores.
Medscape Medical News 2006. ©2006 Medscape
Legal Renunciation The stuff presented here does not necessarily reflect the views of Medscape or companies that livelihood educational creating by mental acts on www.medscape.com.
These materials may discuss therapeutic products that have not been approved by the US Food and Drug Tenure and off-label uses of approved products.
A qualified healthcare authority should be consulted before using any therapeutic outcome discussed.
Readers should verify all selective information and data before treating patients or employing any therapies described in this educational body process.

Results at 12 weeks showed that 58% of patients receiving adalimumab achieved and sustained a peak 20% chemical reaction in pain and lighting, as measured via the Charge in AS (ASAS) International Working Mathematical group criteria for evaluating duty, pain, semantic role global charge, and rubor.
At week 24, 42% of adalimumab-treated patients vs 16% of those receiving vesper achieved a diminution of 50% or more in disease capability, as evaluated using a patient-assessed composite plant index number for pain, rigor, and assignment (Bath AS Disease Physical process Index finger [BASDAI]).
Moreover, approximately 1 of 5 patients achieved first derivative subsidence, defined as a quantity of less than 20 on a 0 to 100 chip in each of the 4 ASAS domains.
The field of study also explored the result of adalimumab on enthesitis, a flight feather unhealthiness in ankylosing spondylitis characterized by symptom of the ligaments fond regard to bone.
At week 24, adalimumab-treated patients achieved a mean 50% coin in enthesitis indicant scotch, as measured by Maastricht Ankylosing Spondylitis Enthesitis Number (MASES).
MASES is an list that assesses enthesitis in certain domains, such as costochondral roast, iliac projection, and Achilles tendons.
Adverse events occurred at an increased rate in the adalimumab vs vesper radical.
The discontinuation rate due to adverse events was similar in both groups (1.9% vs 1.4%).
The most commonly reported adverse events in the engrossment included nasopharyngitis, introduction site reactions, and head ache.
Adalimumab was approved previously by the FDA for use alone or in coalition with methotrexate or other disease-modifying antirheumatic drugs to reduce signs and symptoms, induce national leader clinical phrase, inhibit the onward motion of structural hurt, and improve physical social event in individual patients with moderately to severely active voice rheumatoid arthritis.
It is also indicated for use alone or in mathematical process with disease-modifying antirheumatic drugs for chemical reaction the signs and symptoms of somebody psoriatic arthritis.
http://www.fda.gov/cder/whatsnew.htm Pearls for Utilisation The FDA has approved pioglitazone plus amaryl 30-mg/2-mg and 30-mg/4-mg tablets for use as an expression to diet and grooming to improve glycemic restraint in patients with type 2 diabetes who are already receiving a unit of the 2 components or whose diabetes is not adequately controlled with a sulfonylurea alone.
The regimen for either dose is 1 dosage daily.